Efficacy and safety of laquinimod in multiple sclerosis: current status
about
NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic ImplicationsLaquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target.
P2860
Efficacy and safety of laquinimod in multiple sclerosis: current status
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy and safety of laquinimod in multiple sclerosis: current status
@ast
Efficacy and safety of laquinimod in multiple sclerosis: current status
@en
type
label
Efficacy and safety of laquinimod in multiple sclerosis: current status
@ast
Efficacy and safety of laquinimod in multiple sclerosis: current status
@en
prefLabel
Efficacy and safety of laquinimod in multiple sclerosis: current status
@ast
Efficacy and safety of laquinimod in multiple sclerosis: current status
@en
P2860
P356
P1476
Efficacy and safety of laquinimod in multiple sclerosis: current status
@en
P2093
Shalom Haggiag
P2860
P304
P356
10.1177/1756285613499424
P577
2013-11-01T00:00:00Z